| scholarly article | Q13442814 |
| P50 | author | Michele Caraglia | Q38321049 |
| Raffaele Addeo | Q57427095 | ||
| Sergio Facchini | Q86547274 | ||
| P2093 | author name string | Amalia Luce | |
| Silvia Zappavigna | |||
| P2860 | cites work | Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 |
| Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients | Q28330063 | ||
| Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life | Q33270398 | ||
| Temozolomide for the treatment of metastatic melanoma: a systematic review | Q33301430 | ||
| Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. | Q33345489 | ||
| Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). | Q33348137 | ||
| Fotemustine plus dacarbazine for malignant melanoma. | Q33353557 | ||
| Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study | Q33361043 | ||
| Positive phase II study in the treatment of advanced malignant melanoma with fotemustine | Q33374887 | ||
| Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors | Q33375710 | ||
| Temozolomide in combination with fotemustine in patients with metastatic melanoma | Q33376875 | ||
| A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. | Q33391296 | ||
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial | Q33402830 | ||
| A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma | Q33490446 | ||
| Phase II trial of fotemustine in patients with metastatic malignant melanoma | Q33490747 | ||
| Fotemustine in the treatment of brain primary tumors and metastases | Q33491675 | ||
| Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer | Q33492796 | ||
| Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer | Q33495021 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Treatment options for brain metastases in patients with non-small cell lung cancer | Q35044084 | ||
| Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. | Q35635056 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| Multidisciplinary management of brain metastases | Q36900730 | ||
| The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | Q37644237 | ||
| Therapy and prophylaxis of brain metastases | Q37809862 | ||
| An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting | Q37858468 | ||
| Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? | Q37870216 | ||
| Targeted therapy in brain metastasis | Q38028295 | ||
| Proton inactivation of melanoma cells enhanced by fotemustine | Q39616257 | ||
| Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. | Q40635156 | ||
| A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer | Q40960382 | ||
| Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. | Q42844316 | ||
| Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study | Q43075589 | ||
| O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers | Q43278971 | ||
| Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases | Q43573415 | ||
| Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). | Q43578766 | ||
| Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases | Q44119212 | ||
| A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma | Q44303940 | ||
| Epidemiology of brain tumors: the national survey of intracranial neoplasms | Q44515944 | ||
| Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies | Q44746182 | ||
| Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial | Q44942613 | ||
| Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial | Q45209661 | ||
| Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. | Q46099901 | ||
| Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. | Q46362575 | ||
| Treatment of brain metastases from melanoma | Q46463215 | ||
| Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study | Q46614649 | ||
| Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial | Q48211461 | ||
| Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. | Q48491269 | ||
| Lecture: fotemustine in brain tumors | Q48536975 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases | Q48868052 | ||
| A randomized trial of surgery in the treatment of single metastases to the brain | Q49096659 | ||
| Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma | Q49143256 | ||
| Roentgen-ray therapy of cerebral metastases. | Q51342054 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 729-740 | |
| P577 | publication date | 2013-04-08 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC | |
| P478 | volume | 12 |
| Q27022452 | Advances in treatment of brain metastases from primary non-small cell lung cancer |
| Q38923467 | B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. |
| Q91763994 | Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study |
| Q51748170 | Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. |
| Q38947116 | Immunological effects of chemotherapy and radiotherapy against brain tumors |
| Q35150452 | Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis |
| Q44959749 | Management of intracranial melanomas in the era of precision medicine |
| Q30837718 | The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. |
| Q54974198 | The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). |
Search more.